Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1, First-in-Human, Open-Label, Dose Escalation Study of Talquetamab, a Humanized GPRC5D x CD3 Bispecific Antibody, in Subjects With Relapsed or Refractory Multiple Myeloma

Trial Profile

A Phase 1, First-in-Human, Open-Label, Dose Escalation Study of Talquetamab, a Humanized GPRC5D x CD3 Bispecific Antibody, in Subjects With Relapsed or Refractory Multiple Myeloma

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 05 Feb 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Talquetamab (Primary) ; Talquetamab (Primary) ; Recombinant human serum albumin
  • Indications Multiple myeloma
  • Focus Adverse reactions; First in man; Registrational
  • Acronyms MonumenTAL-1
  • Sponsors Janssen Research & Development; Janssen-Cilag
  • Most Recent Events

    • 12 Dec 2023 Results (n=70; as of 17 Jan 2023) of an updated analysis including all patients from phase 1 and 2 MonumenTAL-1 trials who received 1 of the 2 recommended phase 2 doses of subcutaneous talquetamab and who were exposed to a TCR (prior CAR-T and BsAb) presented at the 65th American Society of Hematology Annual Meeting and Exposition
    • 12 Dec 2023 According to a Janssen media release, results from this trial were featured in a poster presentation at the 2023 American Society of Hematology (ASH) Annual Meeting.
    • 12 Dec 2023 Results presented in the Janssen Media Release.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top